Cited by 674Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerHeat shock proteins research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Open access

Shangary, Sanjeev, Qin, Dongguang, McEachern, Donna, Liu, Meilan, Miller, Rebecca S., Qiu, Su, Nikolovska-Coleska, Zaneta, Ding, Ke, Wang, Guoping, Chen, Jianyong, Bernard, Denzil, Zhang, Jian, Lu, Yipin, Gu, Qingyang, Shah, Rajal B., Pienta, Kenneth J., Ling, Xiaolan, Kang, Sanmao, Guo, Ming, Sun, Yi, Yang, Dajun, Wang, Shaomeng·2008·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0708917105PMC PMC2268798

Open this paper in CoChat — free account

Abstract

We have designed MI-219 as a potent, highly selective and orally active small-molecule inhibitor of the MDM2–p53 interaction. MI-219 binds to human MDM2 with a K i value of 5 nM and is 10,000-fold selective for MDM2 over MDMX. It disrupts the MDM2–p53 interaction and activates the p53 pathway in cells with wild-type p53, which leads to induction of cell cycle arrest in all cells and selective apoptosis in tumor cells. MI-219 stimulates rapid but transient p53 activation in established tumor xenograft tissues, resulting in inhibition of cell proliferation, induction of apoptosis, and complete tumor growth inhibition. MI-219 activates p53 in normal tissues with minimal p53 accumulation and is not toxic to animals. MI-219 warrants clinical investigation as a new agent for cancer treatment.

Integrity signals

Registry

Crossref · 10.1073/pnas.0708917105

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
El‐Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Ce, C., Jackman, J., Pietenpol, J. A., Burrell, M., De, H., & Wang, Y. (1994) · PubMed · Cited by 2,021
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 2

CG Maki, JM Huibregtse, PM Howley Cancer Res 56, 2649–2654 (1996).
WS el-Deiry, JW Harper, PM O'Connor, VE Velculescu, CE Canman, J Jackman, JA Pietenpol, M Burrell, DE Hill, Y Wang, et al. Cancer Res 54, 1169–1174 (1994).

Sorted by citations

Items 101–200 of 674

Organocatalytic stereocontrolled synthesis of 3,3′-pyrrolidinyl spirooxindoles by [3+2] annulation of isocyanoesters with methyleneindolinones
Wang, L., Bai, J., Peng, L., Qi, L., Jia, L., Guo, Y., Luo, X., Xu, X., & Wang, L. (2012) · Chemical Communications · doi:10.1039/c2cc30746d · Cited by 131
Degradation of MDM2 by the Interaction between Berberine and DAXX Leads to Potent Apoptosis in MDM2-Overexpressing Cancer Cells
Zhang, X., Gu, L., Li, J., Shah, N., He, J., Yang, L., Hu, Q., & Zhou, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1546 · Cited by 130
Small molecular weight protein–protein interaction antagonists—an insurmountable challenge?
Dömling, A. S. S. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.04.603 · Cited by 128
New insights into p53 activation
Brooks, C. L., & Gu, W. (2010) · Cell Research · doi:10.1038/cr.2010.53 · Cited by 102
Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer
Rew, Y., & Sun, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500627s · Cited by 125
Discovery of N-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration
Sirisoma, N. S., Pervin, A., Zhang, H., Jiang, S., Willardsen, J. A., Anderson, M. B., MATHER, G. G., Pleiman, C. M., Kasibhatla, S., Tseng, B., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801315b · Cited by 124
Activation of Lung p53 by Nutlin-3a Prevents and Reverses Experimental Pulmonary Hypertension
Mouraret, N., Marcos, É., Abid, S., Gary‐Bobo, G., Saker, M., Houssaini, A., Dubois‐Randé, J., Boyer, L., Boczkowski, J., Dérumeaux, G., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002434 · Cited by 129
The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design
Thompson, R. H., & Eastman, A. R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12139 · Cited by 122
Drugging the undruggable: Transcription therapy for cancer
Yan, C., & Higgins, P. J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.11.002 · Cited by 126
Catalytic Asymmetric exo′‐Selective [3+2] Cycloaddition for Constructing Stereochemically Diversified Spiro[pyrrolidin‐3,3′‐oxindole]s
Awata, A., & Arai, T. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201201249 · Cited by 121
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Yuan, Y., Liao, Y.-M., Hsueh, C.-T., & Mirshahidi, H. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-16 · Cited by 120
A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0581 · Cited by 117
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism
Pal, S., Bhattacharjee, A., Ali, A., Mandal, N. C., Mandal, S. C., & Pal, M. (2014) · Journal of Inflammation · doi:10.1186/1476-9255-11-23 · Cited by 119
A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000329 · Cited by 115
Self-citation
P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
Said, R., Hong, D. S., Warneke, C. L., Lee, J. J., Wheler, J. J., Jankú, F., Naing, A., Falchook, G. S., Fu, S., Piha-Paul, S. A., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.974 · Cited by 115
An Organocatalytic Michael–Michael Cascade for the Enantioselective Construction of Spirocyclopentane Bioxindoles: Control of Four Contiguous Stereocenters
Sun, W., Hong, L., Zhu, G., Wang, Z., Wei, X., Ni, J., & Wang, R. (2014) · Organic Letters · doi:10.1021/ol4034226 · Cited by 114
Analysis of Chemical Shift Changes Reveals the Binding Modes of Isoindolinone Inhibitors of the MDM2-p53 Interaction
Riedinger, C., Endicott, J., Kemp, S. J., Smyth, L. A., Watson, A. F., Valeur, E., Golding, B. T., Griffin, R. J., Hardcastle, I. R., Noble, M. E. M., et al. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8062088 · Cited by 113
One‐Pot Synthesis of Spirooxindole Derivatives Catalyzed by Lipase in the Presence of Water
Chai, S., Lai, Y., Xu, J., Zheng, H., Zhu, Q. X., & Zhang, P. (2011) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201000523 · Cited by 110
A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53
Zhang, Q., Zeng, S. X., Zhang, Y., Zhang, Y.-W., Ding, D., Ye, Q.-Z., Meroueh, S. O., & Lu, H. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100211 · Cited by 110
Core Structure‐Based Design of Organocatalytic [3+2]‐Cycloaddition Reactions: Highly Efficient and Stereocontrolled Syntheses of 3,3′‐Pyrrolidonyl Spirooxindoles
Tan, B., Zeng, X., Leong, W. W. Y., Shi, Z., Barbas, C. F., & Zhong, G. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201103449 · Cited by 107
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106
Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities
Landré, V., Rotblat, B., Melino, S., Bernassola, F., & Melino, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2431 · Cited by 108
p53 and MDM2 in renal cell carcinoma
Noon, A. P., Vlatković, N., Polański, R., Maguire, M., Shawki, H., PARSONS, K. F., & Boyd, M. T. (2010) · Cancer · doi:10.1002/cncr.24841 · Cited by 109
MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice
Mulay, S. R., Thomasová, D., Ryu, M., & Anders, H. (2012) · Kidney International · doi:10.1038/ki.2011.482 · Cited by 104
p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α–mediated down-regulation of CXCL12
Kojima, K., McQueen, T. J., Chen, Y., Jacamo, R. O., Konopleva, M. Y., Shinojima, N., Shpall, E. J., Huang, X., & Andreeff, M. (2011) · Blood · doi:10.1182/blood-2011-02-334136 · Cited by 108
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Wang, S., & Chen, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114334 · Cited by 104
Self-citation
Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations
Azmi, A. S., Wang, Z., Philip, P. A., Mohammad, R. M., & Sarkar, F. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0642 · Cited by 100
Catalytic Asymmetric Synthesis of Spirooxindoles by a Mannich‐Type Reaction of Isothiocyanato Oxindoles
Kato, S., Yoshino, T., Shibasaki, M., Kanai, M., & Matsunaga, S. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203005 · Cited by 100
Apoptosis and Pharmacological Therapies for Targeting Thereof for Cancer Therapeutics
Singh, V., Khurana, A., Navik, U., Allawadhi, P., Bharani, K. K., & Weiskirchen, R. (2022) · Sci · doi:10.3390/sci4020015 · Cited by 102
A covalently bound inhibitor triggers EZH2 degradation through CHIP‐mediated ubiquitination
Wang, X., Cao, W., Zhang, J., Yan, M., Xu, Q., Wu, X., Wan, L., Zhang, Z., Zhang, C., Qin, X., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201694058 · Cited by 100
Self-citation
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 101
The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models
Wang, W., Qin, J., Voruganti, S., Srivenugopal, K. S., Nag, S. A., Patil, S. A., Sharma, H., Wang, M., Wang, H., Buolamwini, J. K., et al. (2014) · Nature Communications · doi:10.1038/ncomms6086 · Cited by 100
Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents
Peltonen, K., Colis, L. C., Liu, H., Jäämaa, S., Moore, H. M., Enbäck, J., Laakkonen, P., Vaahtokari, A., Jones, R. J., af Hällström, T. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012996 · Cited by 107
Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases
Edelmann, M. J., Nicholson, B., & Kessler, B. M. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002031 · Cited by 97
Selective and Potent Proteomimetic Inhibitors of Intracellular Protein–Protein Interactions
Barnard, A., Long, K., Martin, H. L., Miles, J. A., Edwards, T. A., Tomlinson, D. C., Macdonald, A., & Wilson, A. J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410810 · Cited by 98
Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition
Wang, Z., Zheng, M., Li, Z. F., Li, R., Jia, L., Xiong, X., Southall, N. T., Wang, S., Xia, M., Austin, C. P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0891 · Cited by 97
Self-citation
Enantioselective 1,3-dipolar cycloaddition of methyleneindolinones and N,N′-cyclic azomethine imines
Hong, L., Kai, M., Wu, C., Sun, W., Zhu, G., Li, G., Yao, X., & Wang, R. (2013) · Chemical Communications · doi:10.1039/c3cc41507d · Cited by 96
Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53–MDM2 Interaction Useful in Targeted Cancer Therapy
Gupta, A., Bharadwaj, M., Kumar, A., & Mehrotra, R. (2016) · Topics in Current Chemistry · doi:10.1007/s41061-016-0089-0 · Cited by 95
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91
Self-citation
Recent Advances in Green Synthesis of 3,3′‐Spirooxindoles via Isatin–based One–pot Multicomponent Cascade Reactions in Aqueous Medium
Yan, L., & Wang, Y. (2016) · ChemistrySelect · doi:10.1002/slct.201601534 · Cited by 91
Palladium-Catalyzed Diastereoselective Formal [5 + 3] Cycloaddition for the Construction of Spirooxindoles Fused with an Eight-Membered Ring
Niu, B., Wu, X., Wei, Y., & Shi, M. J. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01748 · Cited by 90
Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
Zhao, Y., Bernard, D., & Wang, S. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.4 · Cited by 91
Self-citation
Highly Enantioselective [3 + 2]-Annulation of Isatin-Derived Morita–Baylis–Hillman Adducts with Cyclic Sulfonimines
Wei, F., Huang, H.-Y., Zhong, N., Gu, C., Wang, D., & Liu, L. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b00456 · Cited by 89
“Organo–Metal” Synergistic Catalysis: The 1+1>2 Effect for the Construction of Spirocyclopentene Oxindoles
Sun, W., Zhu, G., Wu, C., Hong, L., & Wang, R. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201201976 · Cited by 87
Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment
Gu, L., Zhang, H., Liu, T., Zhou, S., Du, Y., Xiong, J., Yi, S., Qu, C.-K., Fu, H., & Zhou, M. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.015 · Cited by 86
Small-molecule inhibitors of MDM2 as new anticancer therapeutics
Dickens, M. P., Fitzgerald, R. P., & Fischer, P. M. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.003 · Cited by 90
Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis
Gupta, I., Singh, K., Varshney, N. K., & Khan, S. M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00011 · Cited by 88
1-Isoindolinone scaffold-based natural products with a promising diverse bioactivity
Upadhyay, S. P., Thapa, P., Sharma, R., & Sharma, M. (2020) · Fitoterapia · doi:10.1016/j.fitote.2020.104722 · Cited by 87
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia
Long, J., Parkin, B. L., Ouillette, P. D., Bixby, D. L., Shedden, K., Erba, H. P., Wang, S., & Malek, S. N. (2010) · Blood · doi:10.1182/blood-2010-01-261628 · Cited by 87
Self-citation
Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Wang, W., & Hu, Y. (2011) · Medicinal Research Reviews · doi:10.1002/med.20236 · Cited by 87
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
Garcia, D., Warr, M. R., Martins, C. P., Brown Swigart, L., Passegué, E., & Evan, G. I. (2011) · Genes & Development · doi:10.1101/gad.16722111 · Cited by 83
Targeting Tumor Suppressor Networks for Cancer Therapeutics
Guo, X. E., Ngo, B., Modrek, A. S., & Lee, W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106095151 · Cited by 89
Targeting p53-MDM2-MDMX Loop for Cancer Therapy
Zhang, Q., Zeng, S. X., & Lu, H. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_16 · Cited by 85
Medicinal Chemistry Strategies to Disrupt the p53–MDM2/MDMX Interaction
Lemos, A., Leão, M., Soares, J., Palmeira, A., Pinto, M. M. M., Saraiva, L., & Sousa, M. E. (2016) · Medicinal Research Reviews · doi:10.1002/med.21393 · Cited by 84
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 88
N-alkylated oligoamide α-helical proteomimetics
Campbell, F., Plante, J. P., Edwards, T. A., Warriner, S. L., & Wilson, A. J. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c001164a · Cited by 82
Helix-mediated protein–protein interactions as targets for intervention using foldamers
Edwards, T. A., & Wilson, A. J. (2011) · Amino Acids · doi:10.1007/s00726-011-0880-8 · Cited by 88
E3 Ubiquitin Ligase RNF126 Promotes Cancer Cell Proliferation by Targeting the Tumor Suppressor p21 for Ubiquitin-Mediated Degradation
Zhi, X., Zhao, D. H., Wang, Z., Zhou, Z., Wang, C., Chen, W., Liu, R., & Chen, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0562 · Cited by 85
Highly Stereoselective [3+2] Cycloadditions of Chiral Palladium‐Containing N1‐1,3‐Dipoles: A Divergent Approach to Enantioenriched Spirooxindoles
Li, T., Cheng, B., Fan, S., Wang, Y., Lu, L., & Xiao, W. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201600735 · Cited by 81
Targeting apoptosis pathways in glioblastoma
Eisele, G., & Weller, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.12.012 · Cited by 82
Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice
Wang, W., Qin, J., Voruganti, S., Wang, M., Sharma, H., Patil, S. A., Zhou, J., Wang, H., Mukhopadhyay, D., Buolamwini, J. K., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.001 · Cited by 83
Phosphine-Catalyzed Synthesis of 3,3-Spirocyclopenteneoxindoles from γ-Substituted Allenoates: Systematic Studies and Targeted Applications
Gomez, C., Gicquel, M., Carry, J., Schio, L., Retailleau, P., Voituriez, A., & Marinetti, A. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo302460d · Cited by 82
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 84
An Ultrahigh Affinity d -Peptide Antagonist Of MDM2
Zhan, C., Zhao, L., Wei, X., Wu, X., Chen, X., Yuan, W., Lu, W., Pazgier, M., & Lu, W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3005465 · Cited by 80
Small molecule modulators of protein-protein interactions: selected case studies
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K. R., Jimmidi, R., Jogula, S., & Arya, P. (2014) · Chemical Reviews · doi:10.1021/cr4004049 · Cited by 79
From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Chen, L., Morrow, J. K., Tran, H. T., Phatak, S. S., Du‐Cuny, L., & Zhang, S. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436386 · Cited by 81
Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry
Li, C., Pazgier, M., Li, J., Li, C., Liu, M., Zou, G., Li, Z., Chen, J., Tarasov, S. G., Lu, W., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116814 · Cited by 79
Self-citation
Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles
Aguilar, A., Sun, W., Liu, L., Lu, J., McEachern, D., Bernard, D., Deschamps, J. R., & Wang, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501541j · Cited by 79
Self-citation
Apamin as a Template for Structure‐Based Rational Design of Potent Peptide Activators of p53
Li, C., Pazgier, M., Liu, M., Lu, W., & Lu, W. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200904550 · Cited by 81
Self-citation
The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78
Small-Molecule Inhibitors of the p53-MDM2 Interaction
Vu, B. T., & Vassilev, L. T. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_110 · Cited by 82
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy
Pienta, K. J., Hammarlund, E. U., Austin, R. H., Axelrod, R., Brown, J. S., & Amend, S. R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.016 · Cited by 80
Self-citation
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
Mohammad, R. M., Wu, J., Azmi, A. S., Aboukameel, A., Sosin, A. M., Wu, S., Yang, D., Wang, S., & Al-Katib, A. M. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-115 · Cited by 80
Self-citation
Essential Roles of E3 Ubiquitin Ligases in p53 Regulation
Sane, S., & Rezvani, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020442 · Cited by 78
A computational analysis of binding modes and conformation changes of MDM2 induced by p53 and inhibitor bindings
Chen, J., Wang, J., Zhu, W., & Li, G. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9693-z · Cited by 77
Self-citation
Turning a Scorpion Toxin into an Antitumor Miniprotein
Li, C., Liu, M., Monbo, J., Zou, G., Li, C., Yuan, W., Zella, D., Lu, W., & Lu, W. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8042036 · Cited by 75
Self-citation
The copper-catalyzed asymmetric construction of a dispiropyrrolidine skeleton via 1,3-dipolar cycloaddition of azomethine ylides to α-alkylidene succinimides
Yang, W., Liu, Y., Luo, S., Yu, X., Fossey, J., & Deng, W. (2015) · Chemical Communications · doi:10.1039/c5cc02362a · Cited by 75
Phosphine-catalyzed domino reaction: an efficient method for the synthesis of highly functionalized spirooxazolines
Yang, L., Xie, P., Li, E., Li, X., Huang, Y. Q., & Chen, R. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob26338f · Cited by 74
Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2
Vogel, S., Bauer, M. R., Joerger, A. C., Wilcken, R., Brandt, T., Veprintsev, D. B., Rutherford, T. J., Fersht, A. R., & Boeckler, F. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215060109 · Cited by 74
Structural Ensemble of an Intrinsically Disordered Polypeptide
Mittal, J., Yoo, T. H., Georgiou, G., & Truskett, T. M. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp308984e · Cited by 75
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
Self-citation
Catalytic Enantioselective Synthesis of Spirooxindoles by Oxidative Rearrangement of Indoles
Qian, C., Li, P., & Sun, J. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202015175 · Cited by 72
Targeting Mutant p53 in Human Tumors
Lehmann, B. D., & Pietenpol, J. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0412 · Cited by 74
Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes
Kallen, J. A., Goepfert, A., Blechschmidt, A., Izaac, A., Geiser, M., Tavares, G., Ramage, P., Furet, P., Masuya, K., & Lisztwan, J. H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809096200 · Cited by 75
Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity
Nomura, K., Klejnot, M., Kowalczyk, D., Hock, A. K., Sibbet, G. J., Vousden, K. H., & Huang, D. T. C. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3414 · Cited by 72
A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma
Yi, H., Yan, X., Luo, Q., Yuan, L., Li, B., Pan, W., Zhang, L., Chen, H., Wang, J., Zhang, Y., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0765-8 · Cited by 71
Self-citation
Asymmetric Construction of Bispiro[oxindole-pyrrolidine-rhodanine]s via Squaramide-Catalyzed Domino Michael/Mannich [3 + 2] Cycloaddition of Rhodanine Derivatives with N-(2,2,2-Trifluoroethyl)isatin Ketimines
Song, Y., & Du, D. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.8b01245 · Cited by 71
Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 72
Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors
Michelsen, K., Jordan, J. B., Lewis, J. K., Long, A. M., Yang, E., Rew, Y., Zhou, J., Yakowec, P. S., Schnier, P. D., Huang, X., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305839b · Cited by 72
Podocyte loss involves MDM2 ‐driven mitotic catastrophe
Mulay, S. R., Thomasová, D., Ryu, M., Kulkarni, O. P., Migliorini, A., Bruns, H., Gröbmayr, R., Lazzeri, E., Lasagni, L., Liapis, H., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4193 · Cited by 73
β-Peptides with improved affinity for hDM2 and hDMX
Harker, E. A., Daniels, D. S., Guarracino, D. A., & Schepartz, A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.01.039 · Cited by 74
The p53-MDM2/MDMX axis – A chemotype perspective
Khoury, K., Popowicz, G. M., Holak, T. A., & Dömling, A. S. S. (2011) · MedChemComm · doi:10.1039/c0md00248h · Cited by 71
Regulation of the DNA damage response by ubiquitin conjugation
Brinkmann, K., Schell, M. J., Hoppe, T., & Kashkar, H. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00098 · Cited by 75
The landscape of gene fusions and somatic mutations in salivary gland neoplasms – Implications for diagnosis and therapy
Andersson, M. K., & Stenman, G. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.04.002 · Cited by 69
Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies
Türkez, H., Arslan, M. E., Tatar, A., & Mardinoğlu, A. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105137 · Cited by 68
A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53
Kurokawa, M., Kim, J., Geradts, J., Matsuura, K., Liu, L., Xu, R., Xia, W., Ribar, T. J., Henao, R., Dewhirst, M. W., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003741 · Cited by 68
Self-citation
MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function
Azmi, A. S., Aboukameel, A., Banerjee, S., Wang, Z., Mohammad, M., Wu, J., Wang, S., Yang, D., Philip, P. A., Sarkar, F. H., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.015 · Cited by 67
Self-citation
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Han, X., Wei, W., & Sun, Y. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0010 · Cited by 70
Self-citation
New strategies in soft tissue sarcoma treatment
Ceruso, M. S., El-Ghazzi, N., & Italiano, A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01580-3 · Cited by 71

Authors: Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., Bernard, D., Zhang, J., Lu, Y., Gu, Q., Shah, R. B., Pienta, K. J., Ling, X., Kang, S., Guo, M., Sun, Y., Yang, D., & Wang, S.
Affiliations: University of Michigan (US)
*Comprehensive Cancer Center and Department of Internal Medicine and
Ascenta Therapeutics, Inc., Malvern, PA 19355
ORCID: McEachern, Donna
Liu, Meilan
Qiu, Su
Ding, Ke
Chen, Jianyong
Bernard, Denzil
Zhang, Jian
Lu, Yipin
Shah, Rajal B.
Pienta, Kenneth J.
Guo, Ming
Sun, Yi
Yang, Dajun
Wang, Shaomeng
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2008-03-11
Volume: 105
Issue: 10
Pages: 3933-3938
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0708917105
PMC: PMC2268798
OpenAlex: W1992947288
Cited by: 660
References: 42
Citations by year: 2026: 9 · 2025: 9 · 2024: 16 · 2023: 25 · 2022: 23 · 2021: 22 · 2020: 35 · 2019: 34 · 2018: 29 · 2017: 28 · 2016: 42 · 2015: 43 · 2014: 65 · 2013: 45 · 2012: 67
FWCI: 30.50
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Prostate Cancer Foundation (P30CA046592)
Leukemia and Lymphoma Society
National Institutes of Health
National Cancer Institute (R01CA121279, P50CA069568, P30CA046592)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2 inhibitors, p53 activation, p53-MDM2 interaction, selective apoptosis, tumor growth inhibition, tumor xenografts, oral anticancer drugs, cell cycle arrest
MeSH terms: Administration, Oral, Animals, Antineoplastic Agents, Cell Cycle, Humans, Indoles, Models, Molecular, Neoplasms, Protein Binding, Spiro Compounds, Time Factors, Tumor Suppressor Protein p53, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks